Is Lenacapavir Needed for Individuals Adherent to Daily Oral PrEP?
This Viewpoint discusses the potential advantages of injectable preexposure prophylaxis (PrEP) drugs such as lenacapavir for persons unable to adhere to daily oral HIV PrEP and highlights ways in which lenacapavir and expanded PrEP options could offer tailored and effective ways to better meet the diverse needs of at-risk individuals.
Authors
- Xin Niu (ORCID: https://orcid.org/0000-0002-9136-3434)
- Paul K. Drain (ORCID: https://orcid.org/0000-0002-9569-4097)
Institutions
- University of Washington (US)
- National Clinical Research (US)
Publication Details
- Journal
- JAMA
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1001/jama.2024.22995
- Citations
- 2
- Primary Topic
- HIV/AIDS Research and Interventions
- Type
- article
- Field-Weighted Citation Impact
- 0.78